Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination
with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy
as a first line therapy in participants with locally advanced or metastatic non-squamous
NSCLC with high PD-L1 expression (TC = 50%) and without actionable genomic alterations.

Treatment Sites in Georgia